Related Experiment Videos
Novel approaches to the treatment of chronic graft-versus-host disease
1Unità Operativa di Ematologia e Centro Trapianti Midollo Osseo de Muraglia, Azienda Ospedaliera S. Salvatore di Pesaro, Italy.
Insights
Chronic graft-versus-host disease (cGvHD) remains a major complication after stem cell transplants. Current therapies are only partially effective, necessitating research into novel treatments for this serious condition.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Chronic graft-versus-host disease (cGvHD) is a significant complication in allogeneic hematopoietic stem cell transplant survivors.
- It is a leading cause of long-term morbidity and non-relapse mortality.
- Existing diagnostic, prophylactic, and therapeutic strategies for cGvHD have seen limited evolution over the past two decades.
Purpose of the Study:
- To review current knowledge on conventional and emerging treatment strategies for cGvHD.
- To highlight the limitations of existing therapies and the need for effective treatments.
- To emphasize the importance of clinical trials for evaluating new therapeutic approaches.
Main Methods:
- This review synthesizes information from existing literature on cGvHD treatment.
- It examines both established and novel therapeutic modalities.
- The focus is on understanding disease mechanisms for targeted therapy development.
Main Results:
- Current conventional therapies for cGvHD achieve disease control in approximately 50% of patients.
- No single current therapy is successful for the majority of patients.
- Several alternative approaches are being evaluated for refractory cGvHD with variable success.
Conclusions:
- Effective cGvHD therapy requires targeting underlying disease mechanisms to prevent complications.
- There is an unmet need for therapies that are successful in a larger proportion of patients.
- Further clinical trials are essential to establish the efficacy and safety of new treatments for cGvHD.
Abstract:
Chronic graft-versus-host disease (cGvHD) continues to be the major problem in long-term survivors of allogeneic haematopoietic stem cell transplants and is the principal cause of morbidity and non-relapse mortality. Over the past twenty years, diagnosis, prophylaxis and treatment of cGvHD have slowly evolved. An effective therapy for cGvHD is designed to prevent complications through targeting the disease mechanisms. None of the present therapies for cGvHD are successful in the majority of patients. Conventional drugs in different combinations can control the disease in approximately 50% of patients. Attempts to improve survival have led to evaluation of several alternative approaches in the treatment of refractory cGvHD with varying degrees of success. Clinical trials are needed to establish the role of these new approaches in the treatment of cGvHD as first line or salvage therapy without causing significant side effects. This review summarises the currently available knowledge on conventional and new treatment approaches for cGvHD.